Last reviewed · How we verify
Low Dose - SkQ1 — Competitive Intelligence Brief
phase 3
Mitochondria-targeted antioxidant
Mitochondrial reactive oxygen species (ROS)
Ophthalmology; Age-related degenerative diseases
Small molecule
Live · refreshed every 30 min
Target snapshot
Low Dose - SkQ1 (Low Dose - SkQ1) — Mitotech, SA. SkQ1 is a mitochondria-targeted antioxidant that accumulates in mitochondria to neutralize reactive oxygen species and protect against oxidative damage.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Low Dose - SkQ1 TARGET | Low Dose - SkQ1 | Mitotech, SA | phase 3 | Mitochondria-targeted antioxidant | Mitochondrial reactive oxygen species (ROS) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Mitochondria-targeted antioxidant class)
- Mitotech, SA · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Low Dose - SkQ1 CI watch — RSS
- Low Dose - SkQ1 CI watch — Atom
- Low Dose - SkQ1 CI watch — JSON
- Low Dose - SkQ1 alone — RSS
- Whole Mitochondria-targeted antioxidant class — RSS
Cite this brief
Drug Landscape (2026). Low Dose - SkQ1 — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-skq1. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing